These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 29689646)

  • 41. Impact of commissioning weight-loss surgery for bariatric patients.
    Petty N
    Br J Nurs; 2015 Aug 13-Sep 19; 24(15):776-80. PubMed ID: 26266444
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Review article: Pharmacologic management of obesity - updates on approved medications, indications and risks.
    Lupianez-Merly C; Dilmaghani S; Vosoughi K; Camilleri M
    Aliment Pharmacol Ther; 2024 Feb; 59(4):475-491. PubMed ID: 38169126
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effectiveness of anti-obesity medications approved for long-term use in a multidisciplinary weight management program: a multi-center clinical experience.
    Calderon G; Gonzalez-Izundegui D; Shan KL; Garcia-Valencia OA; Cifuentes L; Campos A; Collazo-Clavell ML; Shah M; Hurley DL; Abu Lebdeh HS; Sharma M; Schmitz K; Clark MM; Grothe K; Mundi MS; Camilleri M; Abu Dayyeh BK; Hurtado Andrade MD; Mokadem MA; Acosta A
    Int J Obes (Lond); 2022 Mar; 46(3):555-563. PubMed ID: 34811486
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Approach to Obesity Treatment in Primary Care: A Review.
    Yanovski SZ; Yanovski JA
    JAMA Intern Med; 2024 Jul; 184(7):818-829. PubMed ID: 38466272
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Letter to the editor: naltrexone sustained-release/bupropion sustained-release for the management of obesity: review of the data to date.
    Buehler AM
    Drug Des Devel Ther; 2015; 9():419-23. PubMed ID: 25609921
    [No Abstract]   [Full Text] [Related]  

  • 46. Real-world primary nonadherence to antiobesity medications.
    Kan H; Bae JP; Dunn JP; Buysman EK; Gronroos NN; Swindle JP; Bengtson LGS; Ahmad N
    J Manag Care Spec Pharm; 2023 Oct; 29(10):1099-1108. PubMed ID: 37594848
    [No Abstract]   [Full Text] [Related]  

  • 47. Evaluation of an online cognitive behavioural therapy weight loss programme as an adjunct to anti-obesity medications and lifestyle interventions.
    Tham M; Chong TW
    Australas Psychiatry; 2020 Apr; 28(2):140-147. PubMed ID: 31523974
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparison of combined bupropion and naltrexone therapy for obesity with monotherapy and placebo.
    Greenway FL; Dunayevich E; Tollefson G; Erickson J; Guttadauria M; Fujioka K; Cowley MA;
    J Clin Endocrinol Metab; 2009 Dec; 94(12):4898-906. PubMed ID: 19846734
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The Effective Use of Anti-obesity Medications.
    Schmitz SH; Aronne LJ
    Gastroenterol Clin North Am; 2023 Dec; 52(4):661-680. PubMed ID: 37919019
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Pharmacological therapy of obesity].
    Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
    G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Naltrexone sustained-release/bupropion sustained-release for the management of obesity: review of the data to date.
    Caixàs A; Albert L; Capel I; Rigla M
    Drug Des Devel Ther; 2014; 8():1419-27. PubMed ID: 25258511
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Clinical and Cost Benefits of Anti-Obesity Medication for US Veterans Participating in the MOVE! Weight Management Program.
    Garvey WT; Cheng M; Ramasamy A; Smolarz BG; Park S; Kumar N; Kim N; DerSarkissian M; Bhak RH; Duh MS; Wu M; Hansen S; Young-Xu Y
    Popul Health Manag; 2023 Feb; 26(1):72-82. PubMed ID: 36735596
    [No Abstract]   [Full Text] [Related]  

  • 53. Next generation of weight management medications: implications for diabetes and CVD risk.
    Wharton S; Serodio KJ
    Curr Cardiol Rep; 2015 May; 17(5):35. PubMed ID: 25894803
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Naltrexone/bupropion for obesity: an investigational combination pharmacotherapy for weight loss.
    Billes SK; Sinnayah P; Cowley MA
    Pharmacol Res; 2014 Jun; 84():1-11. PubMed ID: 24754973
    [TBL] [Abstract][Full Text] [Related]  

  • 55. New medications for treatment of obesity: metabolic and cardiovascular effects.
    Pucci A; Finer N
    Can J Cardiol; 2015 Feb; 31(2):142-52. PubMed ID: 25661549
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pharmacotherapy for the management of obesity.
    Patel D
    Metabolism; 2015 Nov; 64(11):1376-85. PubMed ID: 26342499
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Antiobesity drugs before and after bariatric surgery - how to make the best use of them.
    Šrámková P; Fried M
    Cas Lek Cesk; 2022; 161(3-4):107-113. PubMed ID: 36100447
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Past, Present, and Future of Pharmacologic Therapy in Obesity.
    Rodríguez JE; Campbell KM
    Prim Care; 2016 Mar; 43(1):61-7, viii. PubMed ID: 26896200
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Obesity medications: what does the future look like?
    Butsch WS
    Curr Opin Endocrinol Diabetes Obes; 2015 Oct; 22(5):360-6. PubMed ID: 26313898
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Naltrexone/bupropion for obesity.
    Drug Ther Bull; 2017 Nov; 55(11):126-129. PubMed ID: 29117992
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.